Annika Spitzer
Research Subjects
Research Interests
Annika Spitzer has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Heike Aupperle-Lellbach
Laboklin GmbH & Co. KG, 97688 Bad Kissingen, Germany
2 shared publications - Leonore Aeschlimann
Institute of Animal Pathology, Comparative Pathology Plattform (COMPATH), University of Bern, 3012 Bern, Switzerland
2 shared publications - Martin Spitzer
LABOKLIN GmbH&Co. KG, 97688 Bad Kissingen, Germany
2 shared publications - Robert Klopfleisch
Freie Universität Berlin, Berlin, Germany
2 shared publications - Silvia Weidle
Institute of Pathology, School of Medicine, Technical University of Munich, Trogerstr. 18, 80333 München, Germany
2 shared publications - Simone de Brot
School of Veterinary Medicine and Sciences, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham LE12 5RD, UK
2 shared publications
Latest Publications
- Open Access
- 17 December 2025
- Published by MDPI AG in Veterinary Sciences
- Vol. 12 (12) , 1209
DAXX and ATRX Expression in Canine Prostate and Bladder Cancer Identified by Immunohistochemistry—A Digital Quantitative Pilot Study
The chromatin remodelling proteins DAXX and ATRX are key regulators of genome stability and epigenetic processes. Alterations in their expression have been associated with tumour stage and prognostic outcomes in various human cancer types, whereas their role in veterinary oncology has received little investigation to date. We analysed canine prostate and urinary bladder samples, including 18 prostate carcinomas (12 adenocarcinomas and 6 prostatic urothelial carcinomas), 10 non-malignant prostate tissues, 22 urinary bladder carcinomas, and 6 non-malignant bladder tissues. Nuclear expression of DAXX and ATRX was assessed using fully quantitative digital immunohistochemistry. Overall, DAXX exhibited consistently higher expression than ATRX across benign and malignant samples from the prostate and bladder. DAXX and ATRX expression demonstrated a positive correlation across all samples (ρ = 0.553, p < 0.05), suggesting coordinated regulation. They displayed organ-specific expression patterns: prostate carcinomas showed increased expression of DAXX compared with non-malignant prostate tissues (p < 0.05). In contrast, in the bladder, expression of DAXX and ATRX declined with increasing tumour grade (p < 0.05). Our findings provide new insights into the potential of DAXX and ATRX as biomarkers, offering new insights into their clinical relevance in dogs.
- 17 December 2025
- Published by MDPI AG in Veterinary Sciences
- Vol. 12 (12) , 1209
Open AccessDAXX and ATRX Expression in Canine Prostate and Bladder Cancer Identified by Immunohistochemistry—A Digital Quantitative Pilot Study
The chromatin remodelling proteins DAXX and ATRX are key regulators of genome stability and epigenetic processes. Alterations in their expression have been associated with tumour stage and prognostic outcomes in various human cancer types, whereas their role in veterinary oncology has received little investigation to date. We analysed canine prostate and urinary bladder samples, including 18 prostate carcinomas (12 adenocarcinomas and 6 prostatic urothelial carcinomas), 10 non-malignant prostate tissues, 22 urinary bladder carcinomas, and 6 non-malignant bladder tissues. Nuclear expression of DAXX and ATRX was assessed using fully quantitative digital immunohistochemistry. Overall, DAXX exhibited consistently higher expression than ATRX across benign and malignant samples from the prostate and bladder. DAXX and ATRX expression demonstrated a positive correlation across all samples (ρ = 0.553, p < 0.05), suggesting coordinated regulation. They displayed organ-specific expression patterns: prostate carcinomas showed increased expression of DAXX compared with non-malignant prostate tissues (p < 0.05). In contrast, in the bladder, expression of DAXX and ATRX declined with increasing tumour grade (p < 0.05). Our findings provide new insights into the potential of DAXX and ATRX as biomarkers, offering new insights into their clinical relevance in dogs.
- Open Access
- 12 November 2025
- Published by MDPI AG in Preprints.org
DAXX and ATRX Expression in Canine Prostate and Bladder Cancer Identified by Digital Quantitative Immunohistochemistry
The chromatin remodelling proteins DAXX and ATRX are key regulators of ge-nome stability and epigenetic processes. Alterations in their expression have been as-sociated with tumour stage and prognostic outcomes in various humane cancer types, whereas their role in veterinary oncology has received little investigation to date. We analysed canine prostate and urinary bladder samples, including 18 prostate carcino-mas (12 adenocarcinomas, 6 prostatic urothelial carcinomas), 10 non-malignant pros-tate tissues, 22 carcinomas of the urinary bladder and 6 non-malignant bladder tissues. Nuclear expression of DAXX and ATRX was assessed using fully quantitative digital immunohistochemistry. Overall, DAXX exhibited consistently higher expression than ATRX across benign and malignant samples from the prostate and bladder. DAXX and ATRX expression demonstrated a positive correlation across all prostate (ρ = 0.692, p < 0.05) and bladder (ρ = 0.488, p < 0.05) samples, suggesting coordinated regulation. They displayed organ-specific expression patterns: prostate carcinomas showed increased expression of both proteins compared with non-malignant prostate tissues. In contrast, in the bladder, expression declined with increasing tumour aggressiveness (p < 0.05). Our findings provide new insights into the potential of DAXX and ATRX as bi-omarkers, offering new insights into their clinical relevance in dogs.
- 12 November 2025
- Published by MDPI AG in Preprints.org
Open AccessDAXX and ATRX Expression in Canine Prostate and Bladder Cancer Identified by Digital Quantitative Immunohistochemistry
The chromatin remodelling proteins DAXX and ATRX are key regulators of ge-nome stability and epigenetic processes. Alterations in their expression have been as-sociated with tumour stage and prognostic outcomes in various humane cancer types, whereas their role in veterinary oncology has received little investigation to date. We analysed canine prostate and urinary bladder samples, including 18 prostate carcino-mas (12 adenocarcinomas, 6 prostatic urothelial carcinomas), 10 non-malignant pros-tate tissues, 22 carcinomas of the urinary bladder and 6 non-malignant bladder tissues. Nuclear expression of DAXX and ATRX was assessed using fully quantitative digital immunohistochemistry. Overall, DAXX exhibited consistently higher expression than ATRX across benign and malignant samples from the prostate and bladder. DAXX and ATRX expression demonstrated a positive correlation across all prostate (ρ = 0.692, p < 0.05) and bladder (ρ = 0.488, p < 0.05) samples, suggesting coordinated regulation. They displayed organ-specific expression patterns: prostate carcinomas showed increased expression of both proteins compared with non-malignant prostate tissues. In contrast, in the bladder, expression declined with increasing tumour aggressiveness (p < 0.05). Our findings provide new insights into the potential of DAXX and ATRX as bi-omarkers, offering new insights into their clinical relevance in dogs.